tbuckley/cabot-search huggingface dataset:
Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Locally Advanced, Recurrent, and Metastatic Prostate Cancer—Reply
Authors: Liza Lindenberg, Baris Turkbey, Peter Choyke
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Ban on healthcare workers with HIV performing certain procedures is lifted
Authors: Chris Mahony
Journal: BMJ (2013)

Advances in treatment make it safe to lift an “outdated” ban on HIV positive doctors performing invasive procedures, the chief medical officer for England, Sally Davies, has said.

The Department of Health announced that from next April HIV positive doctors, dentists, and other health workers across the United Kingdom can undertake all clinical work if combination antiretroviral treatment has reduced their plasma viral load to undetectable levels and they are continuing to receive that treatment.

However, HIV positive doctors will have to register with Public Health England, which will monitor their viral load based on quarterly reports from the clinician’s own HIV …
Diploma in Sports and Exercise Medicine (Great Britain and Ireland)
Authors: Kuntal J Patel
Journal: BMJ (2005)

Mainly for doctors in the field of sports medicine, including general practitioners and surgeons. Candidates for this exam must have a minimum of two years' clinical practice or postgraduate training after obtaining full registration.

In 2004 during the basic surgical rotation.

When I went through the curriculum for the diploma, I realised that it would give me an in-depth knowledge of basic sciences and clinical sciences in relation to sports medicine. I wish to pursue further training in orthopaedic surgery, and I am quite sure that studying for the diploma has helped me widen my knowledge in the field of sports medicine.

In-depth …
Exosome miR‐335 as a novel therapeutic strategy in hepatocellular carcinoma
Authors: Fang Wang, Ling Li, Klaus Piontek, Masazumi Sakaguchi, Florin M. Selaru
Journal: Hepatology (2017)

Hepatocellular carcinoma (HCC) is a common and deadly cancer. Most cases of HCC arise in a cirrhotic/fibrotic liver, indicating that environment may play a paramount role in cancer genesis. Previous studies from our group and others have shown that, in desmoplastic cancers, there is a rich intercellular communication between activated, cancer‐associated fibroblasts and cancer cells. Moreover, extracellular vesicles (EVs), or exosomes, have been identified as an important arm of this intercellular communication platform. Finally, these studies have shown that EVs can carry microRNA (miR) species in vivo and deliver them to desmoplastic cancers. The precise role played by activated liver fibroblasts/stellate cells in HCC development is insufficiently known. Based on previous studies, it appears plausible that activated fibroblasts produce signals carried by EVs that promote HCC genesis. In the current study, we first hypothesized and then demonstrated that stellate cell‐derived EVs 1) can be loaded with an miR species of choice (miR‐335‐5p); 2) are taken up by HCC cells in vitro and more importantly in vivo ; 3) can supply the miR‐335‐5p cargo to recipient HCC cells in vitro as well as in vivo ; and 4) inhibit HCC cell proliferation and invasion in vitro as well as induce HCC tumor shrinkage in vivo . Finally, we identified messenger RNA targets for miR‐335 that are down‐regulated after treatment with EV‐miR‐335‐5p. This study informs potential therapeutic strategies in HCC, whereby stellate cell‐derived EVs are loaded with therapeutic nucleic acids and delivered in vivo . (H epatology 2018;67:940–954)
Trusts are urged to cut spending on locums
Authors: Caroline White
Journal: BMJ (2012)

The disconnection between workforce strategy and business planning in NHS trusts is one of the main reasons for the spiralling costs of locum doctors, concludes a report from NHS Professionals, which was set up by the Department of Health to provide flexible staffing to the NHS.

The report says that trusts should undertake a full strategic and operational review of their management of locums to meet their quality, innovation, productivity and prevention (QUIPP) targets, which require spending on temporary staff to be brought down to 2008-9 …
Faculty of Public Health refutes claims it’s not involved in training reform
Authors: Abi Rimmer
Journal: BMJ (2015)

The Faculty of Public Health has refuted claims that it has not been involved with potential changes to medical education and training. 

Speaking at the BMA’s annual conference of public health medicine in London in April, Kitty Mohan, co-chair of the BMA’s Junior Doctors Committee, said she was concerned that public health wasn’t “fully engaged” in the work that was happening on the …
Flow Cytometry Underestimates and Planimetry Overestimates Alveolar Epithelial Type 2 Cell Expansion after Lung Injury
Authors: Nicole L. Jansing, Neesirg Patel, Jazalle McClendon, Elizabeth F. Redente, Peter M. Henson, Rubin M. Tuder, Dallas M. Hyde, Jens R. Nyengaard, Rachel L. Zemans
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
Cytokine kinetic profiles in children with acute lower respiratory tract infection: a post hoc descriptive analysis from a randomized control trial
Authors: A. Fuchs, V. Gotta, M.-L. Decker, G. Szinnai, P. Baumann, J. Bonhoeffer, N. Ritz, G. Baer, G. Berthet, J.M. Bonhoeffer, M. Buettcher, M. Gambon, U. Heininger, B. Mueller, U.B. Schaad, P. Schuetz, D. Trachsel
Journal: Clinical Microbiology and Infection (2018)
Smartphone-based blood pressure monitoring via the oscillometric finger-pressing method
Authors: Anand Chandrasekhar, Chang-Sei Kim, Mohammed Naji, Keerthana Natarajan, Jin-Oh Hahn, Ramakrishna Mukkamala
Journal: Science Translational Medicine (2018)

A smartphone-based device for cuff-less and calibration-free monitoring of systolic and diastolic blood pressure is comparable to cuff-based devices.
A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs): Updated survival analysis.
Authors: Rachna T. Shroff, Milind M. Javle, Lianchun Xiao, Ahmed Omar Kaseb, Gauri R. Varadhachary, Robert A. Wolff, Kanwal Pratap Singh Raghav, Michiko Iwasaki, Peter Masci, Ramesh K. Ramanathan, Daniel H. Ahn, Tanios S. Bekaii-Saab, Mitesh J. Borad
Journal: Journal of Clinical Oncology (2018)

350 Background: BTCs are often diagnosed at an advanced stage and have a poor prognosis. The standard therapy for aBTCs is the combination of GC. However, the median overall survival (mOS) is dismal at 11.7 months (mos) with a median progression free survival (mPFS) of 8 mos. Methods: A single arm, phase II study was conducted at MD Anderson and Mayo Clinic Arizona. Patients (pts) with aBTC were treated at initial dose level of G/C/N (in mg/m 2 ) at 1000/25/125 (n = 30) which was reduced to lower doses due to grade 3/4 hematological (heme) toxicity (tox) - G/C/N: 800/25/100 (n = 30). Cycles were q21 days with restaging q3 cycles until progression. PFS was the primary endpoint (endpt). Using a Bayesian hypothesis test-based design, we assumed mPFS of 8 mos under the null hypothesis (H0), 10 mos under the alternative (H1). Secondary endpts included mOS, RECIST v1.1 response rate (RR), safety and CA19-9 response. Results: 60 pts were enrolled with 51 being response-evaluable having received more than 1 cycle of therapy (age: median 60 yrs [range 31-77], ECOG PS 0/1 (22/38), M/F (33/27), intrahepatic cholangiocarcinoma/extrahepatic/gallbladder (38/9/13). Median follow-up was 14 mos and median number of treatment (trmt) cycles = 5.24. Pts at initial dose level had significant grade 3/4 heme tox: neutropenia, febrile neutropenia, anemia, and thrombocytopenia leading to trmt discontinuation in 6/30 pts. After dose reduction to G/C/N (in mg/m 2 ) at 800/25/100, trmt was better tolerated with only 3 pts experiencing grade 4 heme tox. Non-heme tox were grade 3 in 19 pts: nausea/vomiting, diarrhea, thromboembolic event/CVA, hypokalemia, constipation, cystitis, LFT elevations. The mPFS = 11.4 mos (95% CI: 6.1, 16.1) and mOS = 19.2 (95%CI: 13.6, NA), 1-year survival rate 67.6%. 51 pts evaluable for response: disease control rate (PR+CR+SD)-84.3% and RR-39%. 12 unresectable cases were operated post trmt with 1 pathologic CR. Conclusions: The combination of GCN was well tolerated at adjusted doses and demonstrates encouraging efficacy having met its mPFS endpt and an impressive mOS higher than historical control. These results merit evaluating GC +/-N in a randomized controlled study. Clinical trial information: NCT02392637.
Relationships between markers of neurologic and endothelial injury during critical illness and long-term cognitive impairment and disability
Authors: Christopher G. Hughes, Mayur B. Patel, Nathan E. Brummel, Jennifer L. Thompson, J. Brennan McNeil, Pratik P. Pandharipande, James C. Jackson, Rameela Chandrasekhar, Lorraine B. Ware, E. Wesley Ely, Timothy D. Girard
Journal: Intensive Care Medicine (2018)
Technology as a Tool for Mental Disorders
Authors: Pierre Philip, Etienne De-Sevin, Jean-Arthur Micoulaud-Franchi
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cell-extrinsic hematopoietic impact of Ezh2 inactivation in fetal liver endothelial cells
Authors: Wen Hao Neo, Christopher A. G. Booth, Emanuele Azzoni, Lijun Chi, Paul Delgado-Olguín, Marella F. T. R. de Bruijn, Sten Eirik W. Jacobsen, Adam J. Mead
Journal: Blood (2018)
Norway to change ballot placement scheme for trainee doctors
Authors: Kari Skinningsrud
Journal: BMJ (2011)

Norway’s health minister has proposed changing the lottery system for deciding where junior doctors serve their compulsory training placement because of the growing number of applications from abroad.

The government currently guarantees a training place within less than six months for any doctor applying for a position. The number of applicants who are not Norwegian citizens, however, has increased by more than fivefold between 2006 and 2009, whereas the number of applications from Norwegians has remained relatively stable. Consequently the number of applications …
Long-term survival of gastric cancer patients with positive immunocytochemistry peritoneal washings.
Authors: Katarzyna Marcisz-Grzanka, Paulina Wieszczy, Malgorzata Malinowska, Lucjan Wyrwicz, Tomasz Olesiński
Journal: Journal of Clinical Oncology (2018)

134 Background: The prognosis in gastric cancer is highly dependent on tumor stage at presentation. Surgery still remains the main therapeutic option in gastric cancer patients. However, the efficacy of this treatment may be substantially limited by the risk of peritoneal dissemination. The introduction of intraperitoneal chemotherapy (HIPEC) may affect the long-term outcomes in this group of patients, but high morbidity associated with such treatment provides the rational to identify the correct population of patients for HIPEC. Methods: This is the long-term effect analysis of prospectively observed cohort of patients assessed with immunocytochemistry peritoneal lavage in the single reffereal center. Between January 2002 and November 2004, the total of 140 patients with histologically confirmed gastric cancer were enrolled to the study. Laparotomy and intraoperative peritoneal lavage for immunocytochemistry examination were performed prior to gastrectomy. The fluid recovered was centrifuged and the sediment was fixed in 10% buffered formalin for 24 h, embedded in paraffin and cut into 4 µm-thick sections. Microscopic slides were also stained against cytokeratin 19 (CK-19), cytokeratin AE1/AE3 (CK-AE1/AE3) and mesothelioma marker. All patients were followed up with endpoints of cancer recurrence and mortality. Results: Median overall survival (OS) in patients with immunocytochemical evidence of free cancer cells in peritoneal washes was significantly shorter than in those without (11 [range: 2-55] vs. 45 [range: 1-164] months). The two groups differed significantly in long-term survival (5-year OS rate: 0.0% [0/17] vs. 43.1% [53/123]; 10-year OS rate: 0.0% [0/17] vs. 29.3% [36/123]) (p &lt; 0.001). Positive peritoneal washing immunocytochemistry was an independent poor outcome prognostic factor after correction for all major prognostic factors. Conclusions: Positive peritoneal washing immunocytochemistry correlated with clinical staging of gastric cancer and was associated with poor overall survival (OS). With all patients dying in 5 years, this subgroup of patients defines a clear population for early salvage HIPEC for prospective verification.
Alterations in the Rho pathway contribute to Epstein-Barr virus–induced lymphomagenesis in immunosuppressed environments
Authors: Sung-Yup Cho, Chang Ohk Sung, Jeesoo Chae, Jieun Lee, Deukchae Na, Wonyoung Kang, Jinjoo Kang, Seoyeon Min, Ahra Lee, Eunhye Kwak, Jooyoung Kim, Boram Choi, Hyunsoo Kim, Jeffrey H. Chuang, Hyo-Kyung Pak, Chan-Sik Park, Sanghui Park, Young Hyeh Ko, Dakeun Lee, Jin Roh, Min-Sun Cho, Seongyeol Park, Young Seok Ju, Yun-Suhk Suh, Seong-Ho Kong, Hyuk-Joon Lee, James Keck, Jacques Banchereau, Edison T. Liu, Woo-Ho Kim, Hansoo Park, Han-Kwang Yang, Jong-Il Kim, Charles Lee
Journal: Blood (2018)
I left work three years ago when I had twins. Now they are going to nursery. Could you advise me how to get back in the NHS. I finished my house job in 2003.
Authors: Rebecca Fitzgerald
Journal: BMJ (2007)

Have a career or related problem that needs answering? Can9t find the right person to point you in the right direction? Log on to the Advice Zone for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site. <b>www.bmjcareers.com/advicezone</b>
Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases
Authors: Fengju Chen, Yiqun Zhang, Don L. Gibbons, Benjamin Deneen, David J. Kwiatkowski, Michael Ittmann, Chad J. Creighton
Journal: Clinical Cancer Research (2018)

Purpose: The Cancer Genome Atlas data resources represent an opportunity to explore commonalities across cancer types involving multiple molecular levels, but tumor lineage and histology can represent a barrier in moving beyond differences related to cancer type.Experimental Design: On the basis of gene expression data, we classified 10,224 cancers, representing 32 major types, into 10 molecular-based "classes." Molecular patterns representing tissue or histologic dominant effects were first removed computationally, with the resulting classes representing emergent themes across tumor lineages.Results: Key differences involving mRNAs, miRNAs, proteins, and DNA methylation underscored the pan-cancer classes. One class expressing neuroendocrine and cancer-testis antigen markers represented ∼4% of cancers surveyed. Basal-like breast cancers segregated into an exclusive class, distinct from all other cancers. Immune checkpoint pathway markers and molecular signatures of immune infiltrates were most strongly manifested within a class representing ∼13% of cancers. Pathway-level differences involving hypoxia, NRF2-ARE, Wnt, and Notch were manifested in two additional classes enriched for mesenchymal markers and miR200 silencing.Conclusions: All pan-cancer molecular classes uncovered here, with the important exception of the basal-like breast cancer class, involve a wide range of cancer types and would facilitate understanding the molecular underpinnings of cancers beyond tissue-oriented domains. Numerous biological processes associated with cancer in the laboratory setting were found here to be coordinately manifested across large subsets of human cancers. The number of cancers manifesting features of neuroendocrine tumors may be much higher than previously thought, which disease is known to occur in many different tissues. Clin Cancer Res; 24(9); 2182-93. ©2018 AACR.
Clinical outcomes following biochemical recurrence among patients with Gleason score 9-10 prostate adenocarcinoma.
Authors: Kiri A Sandler, Fang-I Chu, Jay P. Ciezki, Richard Stock, Gregory Stephen Merrick, David Jeffrey Demanes, Daniel Eidelberg Spratt, Eyad I. Abu-Isa, Mark Pomerantz, Ashley Ross, Phuoc T. Tran, Paul L. Nguyen, Trude Baastad Wedde, Wolfgang Lilleby, Daniel Krauss, Ridwan Alam, Michael L. Steinberg, Eric M. Horwitz, Christopher R. King, Amar Upadhyaya Kishan
Journal: Journal of Clinical Oncology (2018)

102 Background: Patients with Gleason score (GS) 9-10 prostate cancer (PCa) have a high risk of early biochemical recurrence (BCR). Salvage therapy options differ depending on the upfront management strategy. Patients who received upfront surgery (RP) may be curable with salvage external beam radiation therapy (EBRT). However those who underwent EBRT or EBRT with a brachytherapy boost (EBRT+BT) are less likely to receive local salvage therapy and are commonly treated with androgen deprivation therapy (ADT). In this study, we examine the risk of distant metastases (DM) and prostate-cancer specific mortality (PCSM) among patients with GS 9-10 PCa who had BCR following RP, EBRT, or EBRT+BT. Methods: 712 patients with GS 9-10 PCa treated between 2000-2013 at 12 institutions who had BCR were included (346 RP, 282 EBRT, 84 EBRT+BT). Time to DM and PCSM were compared between groups using Cox proportional hazards models with propensity score adjustment. Propensity scores were calculated using age, T-stage, PSA, and GS. Results: In patients who had a BCR, incidence rates of DM and PCSM after RP were 40% and 28%. Rates after EBRT were 60% and 46% and after EBRT+BT were 49% and 31%. Median times to DM and PCSM were 3.5 and 4.9 years after RP, 3.7 and 5.1 years after EBRT, and 3.3 and 6.8 years after EBRT+BT. The rates of local salvage RT and systemic salvage therapy among RP patients were 38% and 59%, respectively. Local and systemic salvage rates were 5% and 31% for EBRT patients and 5% and 28% for EBRT+BT patients. EBRT patients had a shorter time interval to DM compared with RP (HR 1.4, p = .02) and EBRT+BT (HR 1.9, p &lt; .01). EBRT patients also had a shorter time interval to PCSM compared with RP (HR 1.5, p = .02). Conclusions: Among patients with GS 9-10 PCa who experience BCR after definitive management, those treated with EBRT have a shorter time interval to DM and PCSM compared with RP and EBRT+BT. While this analysis is confounded by the differential thresholds for diagnosing a BCR after different modalities, it does suggest that outcomes following BCR after EBRT+BT and RP are similar. It also suggests that extreme dose escalation delays the onset of DM and PCSM even after BCR, when compared with conventionally-dosed EBRT alone.
Teaching surgeons non-technical skills could save lives, conference hears
Authors: Abi Rimmer
Journal: BMJ (2015)

Teaching surgeons non-technical skills such as communication and team working could save lives, the director of the Faculty of Surgical Trainers at the Royal College of Surgeons of Edinburgh has said. 

Speaking at a conference on professionalism and excellence in Edinburgh last month, Craig Mcilhenny said that one in 10 patients who were admitted to hospital would experience some form of adverse …
Managing Asthma in Pregnancy (MAP) trial: FENO levels and childhood asthma
Authors: Matthew Morten, Adam Collison, Vanessa E. Murphy, Daniel Barker, Christopher Oldmeadow, John Attia, Joseph Meredith, Heather Powell, Paul D. Robinson, Peter D. Sly, Peter G. Gibson, Joerg Mattes
Journal: Journal of Allergy and Clinical Immunology (2018)
A third of GP training posts are vacant after first recruitment round
Authors: Abi Rimmer
Journal: BMJ (2015)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following A third of GP training posts are vacant after first recruitment round Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
GP suspensions fell in England in 2011-12
Authors: Caroline White
Journal: BMJ (2012)

The number of general practitioners suspended from work in England because of concerns about their professional practice almost halved last year, but the time they spent away from work while suspended rose, new figures from the National Clinical Assessment Service (NCAS) show.1

Forty five GPs were suspended from work in the NHS in 2011-12 (down from 84 the previous year), equivalent to around one GP for every 900 in the workforce. A similar fall in GP suspensions …